- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer ; volume:62 ; number:7 ; day:10 ; month:5 ; year:2023 ; pages:989-996 ; date:7.2023
Clinical pharmacokinetics ; 62, Heft 7 (10.5.2023), 989-996, 7.2023
- Urheber
-
Detert Oude Weme, S. E. H.
Hulskotte, L. M. G.
Vervenne, W. L.
Imholz, A. L. T.
Cremers, R. G. H. M.
Taxis, K.
Reyners, A. K. L.
van Berlo-van de Laar, I. R. F.
Jansman, F. G. A.
Benoist, G. E.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40262-023-01255-1
- URN
-
urn:nbn:de:101:1-2023101808324591002202
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:48 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Detert Oude Weme, S. E. H.
- Hulskotte, L. M. G.
- Vervenne, W. L.
- Imholz, A. L. T.
- Cremers, R. G. H. M.
- Taxis, K.
- Reyners, A. K. L.
- van Berlo-van de Laar, I. R. F.
- Jansman, F. G. A.
- Benoist, G. E.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer
Comment on: “Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer”
Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
Immune evasion strategies of neuroendocrine-like Enzalutamide resistant prostate cancer
Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death
Bioinformatics analysis reveals that CBX2 promotes enzalutamide resistance in prostate cancer
Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease
Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
Enzalutamide inhibits PEX10 function and sensitizes prostate cancer cells to ROS activators
Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer
Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer
Comment on: “Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer”
Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
Immune evasion strategies of neuroendocrine-like Enzalutamide resistant prostate cancer
Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death
Bioinformatics analysis reveals that CBX2 promotes enzalutamide resistance in prostate cancer
Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease
Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
Enzalutamide inhibits PEX10 function and sensitizes prostate cancer cells to ROS activators
Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer
Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer
Comment on: “Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer”
Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
Immune evasion strategies of neuroendocrine-like Enzalutamide resistant prostate cancer
Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death
Bioinformatics analysis reveals that CBX2 promotes enzalutamide resistance in prostate cancer
Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease
Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
Enzalutamide inhibits PEX10 function and sensitizes prostate cancer cells to ROS activators